Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design-Reference-Cited by-同舟云学术

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Published:2012-11-19 Issue:1 Volume:4 Page:91-97
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Cheng Hengmiao¹,Li Chunze¹,Bailey Simon¹,Baxi Sangita M.¹,Goulet Lance¹,Guo Lisa¹,Hoffman Jacqui¹,Jiang Ying¹,Johnson Theodore Otto¹,Johnson Ted W.¹,Knighton Daniel R.¹,Li John¹,Liu Kevin K.-C.¹,Liu Zhengyu¹,Marx Matthew A.¹,Walls Marlena¹,Wells Peter A.¹,Yin Min-Jean¹,Zhu Jinjiang¹,Zientek Michael¹

Affiliation:

1. Cancer Chemistry, ‡PDM, and §Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml300309h

Reference21 articles.

1. High Frequency of Mutations of the PIK3CA Gene in Human Cancers

2. Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

3. The PI3K Pathway As Drug Target in Human Cancer

4. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on phosphatidylinositol-3-kinase (PI3K) and its inhibitors bearing pyrazole or indazole core for cancer therapy;Chemico-Biological Interactions;2024-08

2. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-03-03

3. Targeting autophagy drug discovery: Targets, indications and development trends;European Journal of Medicinal Chemistry;2024-03

4. Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects;European Journal of Medicinal Chemistry;2024-02

5. Dual PI3K/mTOR inhibitor PF-04979064 regulates tumor growth in gastric cancer and enhances drug sensitivity of gastric cancer cells to 5-FU;Biomedicine & Pharmacotherapy;2024-01